fda announcement semaglutide A big win for Wegovy: Weight loss drug first in history to gain approval for reducing heart risks Semaglutide FDA Approval vs Compounded

A reduction in TG concentration by 1 mmol/l (38.7 mg/dl) is associated with a reduction in cardiovascular mortality in patients aged 4049 by about 50%, and in patients aged 8089 by only 15% (HR = 0.85) [361, 362]

We have introduced L-Carnitine in capsule form because the fine powder in the capsules gets absorbed by the body quickly

It's one of the most commonly studied doses, it's generally well tolerated, and it provides flexibility to increase intake later if a higher amount is appropriate.1 35 That flexibility is particularly valuable given the uncertainties surrounding NAC and cancer biology discussed above

Large-scale, long-term follow-up (including open-label extensions and real-world registries) is needed to monitor rebound weight gain after stopping therapy, as early reports suggest weight tends to increase once medication is discontinued (43)